Vemurafenib plus cobimetinib for BRAF-mutant cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Ear, nose & throat, Heart & circulation, Hormones & metabolism, Immune system & allergy, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a cancer that has a BRAF V600 mutation confirmed by a lab test
- You can provide a new tissue biopsy and blood samples for study testing (and sometimes extra samples if you have certain blood-related cancers)
- Your heart and key blood/organ test results meet the trial’s safety cutoffs
- You must not be pregnant or breastfeeding, and you must use reliable birth control during treatment and for 6 months after
- You should not have certain heart rhythm problems, major recent heart events, or certain eye or pancreas problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This study tests whether adding metformin to vemurafenib can shrink advanced melanoma in people with a specific gene change (BRAF V600E). It’s an early-phase trial, so the main goal is to see if the combination is safe and whether it may work better than expected.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.